Study of Bacopa in Gulf War Illness Patients
In plain words A Phase 2 study of bacopa monnieri in people 46 to 78, run by Nova Southeastern University. It plans to enroll about 170 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 46 to 78. Conditions: Gulf War Illness.
- Born in years 1942 to1978
- Served in the Gulf War theater for any period between August 1990 and July 1991
- Meets modified Kansas case definition criteria and CDC case definition for Gulf War Illness (GWI). The modified Kansas definition, which includes the CDC criteria includes:
- Allowance for normal illnesses of aging, such as hypertension and diabetes if the conditions are treated and are in demonstrable stable and normal ranges at the time of screening and assessment.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
BacoMind® (Bacopa monnieri standardized extract); Placebo
Registered summary
Gulf War Illness is a condition that affects multiple major organ systems, resulting in a diverse array of symptoms that include debilitating fatigue, memory and cognition difficulties, headaches, sleep disturbances, gastrointestinal problems, skin rashes, and musculoskeletal/joint pain. This phase II, double masked, randomized, placebo-controlled, two-arm study will evaluate cognitive function as evidence of efficacy of the nutraceutical intervention, Bacopa, on central nervous system symptom management of Gulf War Illness, along with assessments of safety of the intervention.
Where, as registered
1 US site in 1 state.